32 results
Primary objectives:To confirm the lack of effect of 0.5 mg sublingual testosterone on physiological and subjective measures of sexual arousal in women with HSDD. Secondary objective:To confirm the lack of effect of 0.5 mg sublingual testosterone on…
Primary objective: To establish whether concomitant therapy of trastuzumab, bevacizumab with paclitaxel (regimen A) and/or trastuzumab and bevacizumab followed by the combination of trastuzumab, bevacizumab, and paclitaxel at progression (regimen B…
The overall objective of this phase I/II three-part study is to evaluate the benefit of 12 weeks once daily dosing with ASP9521 in a population of patients with metastatic castrate resistant prostate cancer (CRPC) who have failed one or more lines…
Main objective of this study is to test the feasibility and to determine the short and medium term histological cancer control of focal therapy using MR-guided focal laser ablation therapy in the treatment of localised prostate cancer. Secondary…
Primary objectives:- To improve the clinical effectiveness of the p53 synthetic long peptides vaccine by pre-administration of cyclophosphamide.- To evaluate the immunogenicity of a p53 synthetic long peptide vaccine when preceded by administration…
The main objective of this feasibility study is to assess the treatment accuracy of MR-HIFU in patients with breast cancer using a dedicated MR-HIFU breast system. A secondary objective is to determine the safety.
To increase progression-free survival at 3 months.
In this study we want to evaluate the safety, technical efficiency, and volume treatment capabilities of the Philips MR guided HIFU system in the treatment of patients with symptomatic uterine fibroids. This information is required for CE labelling…
Primary objective:To evaluate the objective response rate (ORR) of AZD1775 in combination with gemcitabine, carboplatin, paclitaxel,or PLD in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancerSecondary…
The overall study aim is to determine the efficacy rate of complete ablation for the most promising types of thermal ablation (RFA, MWA or CA) technique for patients with early stage breast cancer (cT1N0M0) without an extensive component of DCIS (…
In this feasibility study, we will validate the value of the preoperative [89Zr]trastuzumab PET/CT imaging to identify HER2 positive primary breast cancer and the possibility to predict pathological complete response.
Primary objective:- To assess the efficacy of niraparib in subjects with measurable mCRPC and who have either biallelic DNA-repair anomalies in BRCA (BRCA 1 and BRCA 2 or germline BRCA. Secondary objectives:- To assess the efficacy of niraparib in…
To assess toxicity of MRI-guided focal salvage high-dose-rate brachytherapy (HDR-BT) in patients with locally recurrent prostate cancer. Secondary objectives are quality of life, biochemical disease free survival, dose restrictions, technical…
Objective procedure 1:To assess the technical feasibility and safety of in-vivo focal imaging with CLE and OCT.Objective procedure 2: Primary Objective: To identify and define characteristics of prostate cancer on CLE and OCT and compare this with…
Determine the efficacy and safety (using objective response rate) of tremelimumab in patients with advanced solid tumors (UBC, PDAC, TNBC).
The primary objective is to investigate if thermal ablation of breast tumors less than 2cm with < 25% DCIS is effective in terms of the number of tumors in which complete ablation is found on pathology result.
To investigate the potential of atosiban as a treatment for pain caused by endometriosis.
The primary aim of this first line 177Lu-PSMA RLT study is to evaluate the clinical efficacy in castration resistant metastatic prostate cancer. Secondary aims are to assess the progression free survival (radiographic, clinical or PSA progression…
This study has been transitioned to CTIS with ID 2023-506987-15-00 check the CTIS register for the current data. 1) Objective: To evaluate the safety and tolerability of the pembrolizumab combination therapy.2) Objective: To estimate PSA response…
This study has been transitioned to CTIS with ID 2024-510634-41-00 check the CTIS register for the current data. Cohort 1 - LN-145 monotherapy in patients who have progressed during or following systemic therapy for recurrent, metastatic, or…